Get the Stockscreener App
0.00
100.00%
-0.021
Virpax Pharmaceuticals Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.021
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-13.24M
P/E Ratio:
0.00
EPS:
-8.83
Net Cash Flow:
$-16.85M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-97.91%
1Y Performance:
-99.74%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.021
52-Week Range:
$0.00
$0.2869
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Name
Virpax Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare VRPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.00 | 0 | 0 | -13.24M | -16.85M | -8.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Virpax Pharmaceuticals Inc Stock (VRPX) Latest News
Analyzing Virpax Pharmaceuticals (NASDAQ:VRPX) and IMV (OTCMKTS:IMVIQ) - Defense World
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
Virpax Pharmaceuticals, Inc.Common Stock (NQ: - FinancialContent
Nanotechnology Stocks To Watch Today – September 1st - Defense World
Head-To-Head Comparison: Virpax Pharmaceuticals (NASDAQ:VRPX) vs. Evotec (OTCMKTS:EVTCY) - Defense World
Virpax reports positive study results for pain management drug - MSN
Top Nanotechnology Stocks To Follow Today – August 25th - Defense World
Promising Nanotechnology Stocks To Watch Now – July 16th - Defense World
Promising Nanotechnology Stocks To Watch NowJuly 16th - MarketBeat
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Down 2.9% – Should You Sell? - Defense World
Promising Nanotechnology Stocks To Add to Your Watchlist – July 9th - Defense World
Top Nanotechnology Stocks To Follow NowJuly 10th - MarketBeat
Promising Nanotechnology Stocks To Add to Your WatchlistJuly 9th - MarketBeat
Nanotechnology Stocks To Watch Today – July 7th - Defense World
Nanotechnology Stocks To Research – July 3rd - Defense World
Best Nanotechnology Stocks To Add to Your WatchlistJune 16th - MarketBeat
Top Nanotechnology Stocks Worth WatchingJune 17th - MarketBeat
Best Nanotechnology Stocks To Keep An Eye OnJune 15th - MarketBeat
Nanotechnology Stocks To Watch NowJune 14th - MarketBeat
Promising Nanotechnology Stocks To ResearchJune 11th - MarketBeat
Nanotechnology Stocks To ResearchJune 8th - MarketBeat
Nanotechnology Stocks To Follow NowJune 9th - MarketBeat
Best Nanotechnology Stocks To Follow Today – May 31st - Defense World
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading 4.4% Higher – Still a Buy? - Defense World
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Up 5.5% – Here’s What Happened - Defense World
VRPX Stock Price and Chart — OTC:VRPX - TradingView
VRPX stock plunges to 52-week low, touches $1.07 - Investing.com Australia
Virpax Pharmaceuticals Faces Nasdaq Delisting Notice and Leadership Changes - TipRanks
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com
Virpax receives positive Probudur™ results for dose range study - TradingView
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET - MyChesCo
Could This Needle-Free COVID Vaccine Technology Transform Vaccine Delivery? - Stock Titan
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - Stock Titan
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Virpax lauds Nanomerics’ MET study with no severe side effects - Investing.com India
Virpax lauds Nanomerics’ MET study with no severe side effects By Investing.com - Investing.com South Africa
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Yahoo Finance
Virpax Pharmaceuticals Announces Positive Results from U.S. Army Study on Probudur™ - Kalkine Media
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering - FinancialContent
Virpax Pharmaceuticals sets public offering at $0.20 per share - Investing.com
Virpax Pharmaceuticals enacts reverse stock split - Investing.com
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Virpax Pharmaceuticals appoints new CFO By Investing.com - Investing.com Canada
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
VRPX stock touches 52-week low at $0.46 amid market challenges - Investing.com
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com
Virpax Pharmaceuticals Inc Stock (VRPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Cap:
|
Volume (24h):